Oppenheimer Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a price target of $52.00. The company’s shares closed yesterday at $36.30.

Jones covers the Healthcare sector, focusing on stocks such as Ventyx Biosciences, Perspective Therapeutics, and Corbus Pharmaceuticals. According to TipRanks, Jones has an average return of 28.0% and a 37.35% success rate on recommended stocks.

Kymera Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $43.91, which is a 20.96% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $46.00 price target.

KYMR market cap is currently $2.22B and has a P/E ratio of -14.39.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KYMR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kymera Therapeutics (KYMR) Company Description:

Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera’s Pegasus targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade the intractable of proteins, and advance new treatment options for patients.